Hematologia Geral

Diretriz ESAIC/ESRA | Anestesia regional em pacientes em uso de medicamentos antitrombóticos.

12 Jul, 2022 | 11:57h

Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines – European Journal of Anaesthesia

Comentário no Twitter

Just saw this from 2/22-More reasonable recommendations than ASRA for timeframe to stop Xa's before regional anesthesia (not 96hrs) but including drug levels in some recs
Regional anaesthesia in pts on antithrombotic drugs: Joint ESAIC/ESRA guidelines https://t.co/PrF72HFWzG

— Steven Cohn, MD (@preopconsult) July 10, 2022

Estudo randomizado | Plasma convalescente neutralizante de COVID-19 não traz benefícios a adultos internados com a doença.

11 Jul, 2022 | 13:58h

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized with COVID-19: A Blinded Randomized Placebo-Controlled Trial – CHEST

Comentário: Study shows convalescent plasma doesn’t benefit severely ill patients hospitalized with COVID-19 – Vanderbilt University Medical Center

Revisão | Doença falciforme.

8 Jul, 2022 | 11:28h

Sickle Cell Disease: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Sickle Cell Disease – JAMA

Atualizações de 2021 sobre coagulação e transfusão.

8 Jul, 2022 | 11:09h

Coagulation and Transfusion Updates from 2021 – Journal of Cardiothoracic and Vascular Anesthesia

M-A | Anticoagulantes orais diretos vs. antagonistas da vitamina K em pacientes com fibrilação atrial com bioprótese de válvula cardíaca.

8 Jul, 2022 | 10:56h

An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve – Frontiers in Cardiovascular Medicine

M-A | Anticoagulantes para tromboprofilaxia em pacientes agudos internados.

6 Jul, 2022 | 11:26h

Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis – The BMJ

Casos EM | Os 7 “T” dos protocolos de hemorragia maciça.

6 Jul, 2022 | 10:44h

EM Cases: The 7 Ts of Massive Hemorrhage Protocols – emDocs

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

Dois novos estudos mostram que a enoxaparina não tem benefício na tromboprofilaxia primária de pacientes ambulatoriais sintomáticos com COVID-19.

4 Jul, 2022 | 12:23h

Estudo 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Estudo 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Comentários:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (necessário cadastro gratuito)

Comentário no Twitter (fio – clique para saber mais)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials🧵

— The Lancet Haematology (@TheLancetHaem) June 30, 2022

Análise de eventos tromboembólicos e trombocitopênicos após vacinação contra COVID-19 com vacinas da AstraZeneca, da Pfizer e da Moderna em 3 países nórdicos.

19 Jun, 2022 | 15:40h

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open